Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Research on the gut microbiome has triggered a 'revolution' in nutritional science, and in the last few years, dietary fiber ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

More and more people are taking weight loss injectables like Wegovy and Mounjaro — and pharmacy experts are worried that not ...

Although Novo Nordisk and Eli Lilly are the main players in the GLP-1 arena, a number of other pharmaceutical companies are ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

If you are looking to invest in top growth stocks, these companies can experience more volatility than the average stock.

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...